Literature DB >> 15364968

GB virus type C: a beneficial infection?

Jack T Stapleton1, Carolyn F Williams, Jinhua Xiang.   

Abstract

Mesh：

Year:  2004        PMID： 15364968      PMCID： PMC516331          DOI： 10.1128/JCM.42.9.3915-3919.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  15 in total

Review 1.  Long-term non-progression in HIV infection: clinico pathological issues.

Authors:  S Rowland-Jones
Journal:  J Infect       Date:  1999-03       Impact factor: 6.072

2.  Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells.

Authors:  J Xiang; S Wünschmann; W Schmidt; J Shao; J T Stapleton
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile.

Authors:  Giuseppe Nunnari; Luciano Nigro; Filippo Palermo; Massimo Attanasio; Annemarie Berger; Hans W Doerr; Roger J Pomerantz; Bruno Cacopardo
Journal:  Ann Intern Med       Date:  2003-07-01       Impact factor: 25.391

4.  Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.

Authors:  Jinhua Xiang; Sarah L George; Sabina Wünschmann; Qing Chang; Donna Klinzman; Jack T Stapleton
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

5.  A model-based estimate of the mean incubation period for AIDS in homosexual men.

Authors:  K J Lui; W W Darrow; G W Rutherford
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

6.  Active or prior GB virus C infection does not protect against vertical transmission of HIV in coinfected women from Tanzania.

Authors:  Amy C Weintrob; John D Hamilton; Christine Hahn; Donna Klinzman; Gustav Moyo; Dietmar Zdunek; Georg Hess; Daniel K Benjamin; Jack T Stapleton
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

7.  Persistent GB virus C infection and survival in HIV-infected men.

Authors:  Carolyn F Williams; Donna Klinzman; Traci E Yamashita; Jinhua Xiang; Philip M Polgreen; Charles Rinaldo; Chenglong Liu; John Phair; Joseph B Margolick; Dietmar Zdunek; Georg Hess; Jack T Stapleton
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

8.  Regulation of CC chemokine receptor 5 in hepatitis G virus infection.

Authors:  Jacob Nattermann; Hans-Dieter Nischalke; Bernd Kupfer; Jürgen Rockstroh; Lothar Hess; Tilman Sauerbruch; Ulrich Spengler
Journal:  AIDS       Date:  2003-07-04       Impact factor: 4.177

Review 9.  GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals.

Authors:  Philip M Polgreen; Jinhua Xiang; Qing Chang; Jack T Stapleton
Journal:  Microbes Infect       Date:  2003-11       Impact factor: 2.700

Review 10.  GB virus type C/Hepatitis G virus.

Authors:  Jack T Stapleton
Journal:  Semin Liver Dis       Date:  2003-05       Impact factor: 6.115
View more
  23 in total

1.  The evolution of HIV-1 and the origin of AIDS.

Authors:  Paul M Sharp; Beatrice H Hahn
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-08-27       Impact factor: 6.237

2.  GB virus type C infection polarizes T-cell cytokine gene expression toward a Th1 cytokine profile via NS5A protein expression.

Authors:  Robert T Rydze; Jinhua Xiang; James H McLinden; Jack T Stapleton
Journal:  J Infect Dis       Date:  2012-04-25       Impact factor: 5.226

Review 3.  A novel T cell evasion mechanism in persistent RNA virus infection.

Authors:  Jack T Stapleton; Jinhua Xiang; James H McLinden; Nirjal Bhattarai; Ernest T Chivero; Donna Klinzman; Thomas M Kaufman; Qing Chang
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

4.  Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients.

Authors:  Farnaz Vahidnia; M Petersen; G Rutherford; M Busch; S Assmann; J T Stapleton; B Custer
Journal:  J Infect Dis       Date:  2012-03-20       Impact factor: 5.226

5.  Deep sequencing identifies two genotypes and high viral genetic diversity of human pegivirus (GB virus C) in rural Ugandan patients.

Authors:  Ria R Ghai; Samuel D Sibley; Michael Lauck; Jorge M Dinis; Adam L Bailey; Colin A Chapman; Patrick Omeja; Thomas C Friedrich; David H O'Connor; Tony L Goldberg
Journal:  J Gen Virol       Date:  2013-09-28       Impact factor: 3.891

6.  Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.

Authors:  James H McLinden; Thomas M Kaufman; Jinhua Xiang; Qing Chang; Donna Klinzman; Alfred M Engel; Georg Hess; Urban Schmidt; Michael Houghton; Jack T Stapleton
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

7.  Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood Recipients.

Authors:  Marion C Lanteri; Farnaz Vahidnia; Sylvia Tan; Jack T Stapleton; Philip J Norris; John Heitman; Xutao Deng; Sheila M Keating; Don Brambilla; Michael P Busch; Brian Custer
Journal:  J Infect Dis       Date:  2014-11-25       Impact factor: 5.226

8.  Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia.

Authors:  I E Souza; J B Allen; J Xiang; D Klinzman; R Diaz; S Zhang; K Chaloner; D Zdunek; G Hess; C F Williams; L Benning; J T Stapleton
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

9.  GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

Review 10.  GB virus type C interactions with HIV: the role of envelope glycoproteins.

Authors:  Emma L Mohr; Jack T Stapleton
Journal:  J Viral Hepat       Date:  2009-09-15       Impact factor: 3.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.